222 related articles for article (PubMed ID: 31364863)
41. Historical and pathological overview of Castleman disease.
Nishimura MF; Nishimura Y; Nishikori A; Yoshino T; Sato Y
J Clin Exp Hematop; 2022 Jun; 62(2):60-72. PubMed ID: 35474035
[TBL] [Abstract][Full Text] [Related]
42. Multicentric Castleman disease of hyaline‑vascular variant with paraneoplastic pemphigus results in abnormal lung function: Report of 3 cases.
Cen J; Zeng W; Pan M; Qiu Y; Zhang J
Exp Ther Med; 2023 Jun; 25(6):269. PubMed ID: 37206548
[TBL] [Abstract][Full Text] [Related]
43. The full spectrum of Castleman disease: 273 patients studied over 20 years.
Oksenhendler E; Boutboul D; Fajgenbaum D; Mirouse A; Fieschi C; Malphettes M; Vercellino L; Meignin V; Gérard L; Galicier L
Br J Haematol; 2018 Jan; 180(2):206-216. PubMed ID: 29143319
[TBL] [Abstract][Full Text] [Related]
44. A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease.
Butzmann A; Kumar J; Sridhar K; Gollapudi S; Ohgami RS
Biology (Basel); 2021 Mar; 10(4):. PubMed ID: 33804823
[TBL] [Abstract][Full Text] [Related]
45. Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan.
Murakami M; Johkoh T; Hayashi S; Ohshima S; Mizuki M; Nakatsuka SI; Tomobe M; Kuroyanagi K; Nakasone A; Nishimoto N
Mod Rheumatol; 2020 Sep; 30(5):843-851. PubMed ID: 31829070
[No Abstract] [Full Text] [Related]
46. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.
Zhang L; Dong YJ; Peng HL; Li H; Zhang MZ; Wang HH; Liu QH; Su LP; Zhong LY; Wu WJ; Huang L; Yan XJ; Fan L; Tang WJ; Li ZL; Bi LT; Li Y; Gao GX; Gao L; Liu TB; Wei YQ; Liu Y; Yu L; Zhou H; Sun CY; Qian WB; Zou DH; Zhang HL; Ding KY; Wang XB; Bai O; Huang WR; Chen B; Yang L; Song J; Gao D; Chen T; Luo J; Wang SY; Ma LM; Fajgenbaum DC; Li J;
Lancet Reg Health West Pac; 2023 May; 34():100720. PubMed ID: 37283978
[TBL] [Abstract][Full Text] [Related]
47. Clinical dissection of multicentric Castleman disease.
Shin DY; Jeon YK; Hong YS; Kim TM; Lee SH; Kim DW; Kim I; Yoon SS; Heo DS; Park S; Kim BK
Leuk Lymphoma; 2011 Aug; 52(8):1517-22. PubMed ID: 21585280
[TBL] [Abstract][Full Text] [Related]
48. Unicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2021; 67(8):465-473. PubMed ID: 35459366
[TBL] [Abstract][Full Text] [Related]
49. Quantitative analysis of a rare disease network's international contact database and E-repository provides insights into biobanking in the electronic consent era.
Suarez A; Reilly C; Fajgenbaum DC
Orphanet J Rare Dis; 2019 Jul; 14(1):173. PubMed ID: 31296233
[TBL] [Abstract][Full Text] [Related]
50. [Analysis of the clinicopathologic features as well as diagnosis and treatment of 59 patients with Castleman disease].
Wang J; Liang LJ; Wang YM; Mei ZY; Liu YZ; Liu LN; Fang BJ; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):666-670. PubMed ID: 32942821
[No Abstract] [Full Text] [Related]
51. Imaging of Castleman Disease.
Pitot MA; Tahboub Amawi AD; Alexander LF; LeGout JD; Walkoff L; Navin PJ; Kawashima A; Wood AJ; Dispenzieri A; Venkatesh SK
Radiographics; 2023 Aug; 43(8):e220210. PubMed ID: 37471247
[TBL] [Abstract][Full Text] [Related]
52. Multicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
[TBL] [Abstract][Full Text] [Related]
53. Rapid Clinical Improvement of Multicentric Castleman Disease (MCD) with Renal Involvement Following Treatment with Tocilizumab: AA Amyloidosis as a Possible Renal Involvement of MCD.
Temmoku J; Sasajima T; Kuroda T; Sumichika Y; Saito K; Yoshida S; Matsumoto H; Fujita Y; Matsuoka N; Asano T; Sato S; Yamada T; Hashimoto Y; Migita K
Tohoku J Exp Med; 2023 Mar; 259(4):285-291. PubMed ID: 36653160
[TBL] [Abstract][Full Text] [Related]
54. [Castleman disease. Histopathological and immunohistochemical analysis of 39 cases].
Sevilla-Lizcano DB; Frias-Soria CL; Ortiz-Hidalgo C
Gac Med Mex; 2017; 153(5):550-558. PubMed ID: 29099112
[TBL] [Abstract][Full Text] [Related]
55. Hyaline Vascular Variant of Castleman Disease of the Tonsil in an Adolescent: A case Report.
Kishore A; Rana N; Kumar A; Kashyap V; Jebaying Y
Indian J Otolaryngol Head Neck Surg; 2024 Feb; 76(1):1062-1065. PubMed ID: 38440559
[TBL] [Abstract][Full Text] [Related]
56. The role of interleukin 6 in the pathogenesis and therapy of Castleman disease - an immunologist's perspective.
Milota T; Střížová Z; Sobotková M; Bartůňková J
Cas Lek Cesk; 2023; 162(2-3):106-111. PubMed ID: 37474295
[TBL] [Abstract][Full Text] [Related]
57. Multicentric Plasma-Cell Type Castleman Disease Masquerading As Hodgkin Lymphoma: A Case Report.
Ekwere TA; Eziagu UB
J Lab Physicians; 2020 Dec; 12(3):225-229. PubMed ID: 33268942
[TBL] [Abstract][Full Text] [Related]
58. Report of six kidney disease-associated Castleman's disease cases.
Sui Y; Zhao D
Clin Nephrol; 2015 Dec; 84(6):344-52. PubMed ID: 26445003
[TBL] [Abstract][Full Text] [Related]
59. Clinical and pathological characteristics of Castleman disease: an observational study in a Spanish tertiary hospital.
González-García A; Patier de la Peña JL; García-Cosio M; Sarhane Y; Sánchez Díaz C; Barbolla Díaz I; López Rodríguez M; Moreno MÁ; Villarubia J; Manzano L
Leuk Lymphoma; 2019 Dec; 60(14):3442-3448. PubMed ID: 31305183
[TBL] [Abstract][Full Text] [Related]
60. Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key.
Zhou QY
World J Clin Cases; 2022 Feb; 10(5):1536-1547. PubMed ID: 35211591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
